Immunome (IMNM) CEO granted 360,000 options and 180,000 RSUs
Rhea-AI Filing Summary
Immunome Inc. granted equity awards to President and CEO Clay B. Siegall on July 23, 2026. He received 180,000 RSUs, with 25% vesting on each anniversary of the grant date, and 360,000 stock options with a $22.01 exercise price, 25% vesting on July 23, 2027 and the remainder in equal monthly installments thereafter, all subject to continued service. Following the RSU grant, he directly holds 870,704 common shares, in addition to the newly granted options.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 180,000 shares
Net Buy
2 txns
Insider
SIEGALL CLAY B
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) F2 | 360,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 180,000 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (right to buy) — 360,000 shares (Direct);
Common Stock — 870,704 shares (Direct)
Footnotes (2)
- F1. Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date.
- F2. 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Key Figures
RSUs granted: 180,000 shares
Stock options granted: 360,000 options
Option exercise price: $22.01 per share
+2 more
5 metrics
RSUs granted
180,000 shares
Restricted stock units granted to President and CEO on July 23, 2026
Stock options granted
360,000 options
Employee stock options granted on July 23, 2026
Option exercise price
$22.01 per share
Exercise price of the 360,000 stock options granted to the CEO
Option expiration date
July 22, 2036
Expiration date of the employee stock options granted
Shares held after grant
870,704 shares
Direct common stock holdings of the CEO after the RSU grant
Key Terms
restricted stock units ("RSUs"), contingent right, continuous service, Employee Stock Option (right to buy)
4 terms
restricted stock units ("RSUs") financial
"Represents the number of shares of the Issuer's common stock underlying restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
contingent right financial
"Each RSU represents the contingent right to receive one share of Common Stock upon settlement."
continuous service financial
"subject to the Reporting Person's continuous service through each such vesting date."
Employee Stock Option (right to buy) financial
"security title: Employee Stock Option (right to buy)"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity awards did Immunome (IMNM) grant to its CEO in this Form 4?
Immunome granted CEO Clay B. Siegall 180,000 RSUs and 360,000 stock options on July 23, 2026. The RSUs convert one-for-one into common stock upon vesting, while the options carry a $22.01 exercise price and long-dated expiration.
How do the 180,000 RSUs for Immunome (IMNM) CEO vest over time?
The 180,000 RSUs vest and settle into common stock in four equal annual installments of 25%. Each 25% tranche vests on the anniversary of the July 23, 2026 grant date, conditioned on the CEO’s continuous service through each vesting date.
What are the key terms of the 360,000 stock options granted by Immunome (IMNM)?
The CEO received 360,000 employee stock options with a $22.01 exercise price expiring on July 22, 2036. 25% vest on July 23, 2027, and the remaining options vest in equal monthly installments thereafter, subject to continued service.
Were the Immunome (IMNM) CEO’s reported awards made under a Rule 10b5-1 trading plan?
The awards were reported as grants, and the Rule 10b5-1 trading plan checkbox was not marked as applicable. This indicates the reported transactions were not affirmatively designated as occurring under a pre-arranged Rule 10b5-1 trading plan.